Precision Therapeutics to present clinical data of ChemoFx chemoresponse assay at WAGO meeting

Precision Therapeutics, Inc., a life science company that develops personalized medicine products for individualizing cancer care, today announced that a clinical study which demonstrates the feasibility of the ChemoFx^® chemoresponse assay to identify patients unlikely to respond to first-line therapy has been accepted for presentation at the 2013 Annual Meeting of the Western Association of Gynecologic Oncologists (WAGO). The meeting will be held from June 27-29, 2013 at the W Seattle in Seattle, Washington.

“We are very excited to be presenting this significant data at the WAGO Annual Meeting”

"We are very excited to be presenting this significant data at the WAGO Annual Meeting," said Sean McDonald, President and CEO of Precision Therapeutics. "This study addresses the critical clinical question of how to predict resistance to first-line therapy in ovarian cancer. No personalized chemotherapy diagnostic on the market today can identify primary ovarian cancer patients who are resistant to first-line, standard of care therapy. We believe the results of this study will have a profound impact on improving patient outcomes in the treatment of this devastating disease."

Recurrence following primary chemotherapy remains a major challenge in the treatment of epithelial ovarian cancer. Though response rates to first-line platinum- and taxane-based chemotherapy therapy are high, approximately 80% of patients diagnosed with epithelial ovarian cancer will relapse and may benefit from subsequent therapies. For patients that relapse, including the 25% of patients who will have platinum-refractory or platinum-resistant disease (i.e., disease that progresses while on a platinum-based regimen or recurs within 6 months of completion of a platinum-based regimen), clinical trials should be considered. For patients who do not enter a trial, there is a vast selection of equivalent, NCCN-recommended chemotherapy agents from which a doctor may choose.